NCT03195491 - A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

December 25, 2017

Primary Completion Date

June 8, 2021

Study Completion Date

June 8, 2021

Conditions

Lung CancerNon-Small Cell Lung Cancer

Interventions

BIOLOGICAL

Nivolumab

Intravenous infusion administered over 30 minutes at 240 mg

Trial Locations (30)

10700

Local Institution, Bangkok

40002

Local Institution, Khon Kaen

100001

Local Institution, Beijing

100031

Local Institution, Beijingcun

100142

Local Institution, Beijing

100730

Local Institution, Beijing

101149

Local Institution, Beijing

110042

Local Institution, Shenyang

130012

Local Institution, Changchun

130021

Local Institution, Changchun

150081

Local Institution, Harbin

200025

Local Institution, Shanghai

200030

Local Institution, Shanghai

200032

Local Institution, Shanghai

210002

Local Institution, Nanjing

210008

Local Institution, Nanjing

250031

Local Institution, Jinan

300222

Local Institution, Tianjin

310000

Local Institution, Hangzhou

310003

Local Institution, Hangzhou

310022

Local Institution, Hangzhou

350014

Local Institution, Fuzhou

410013

Local Institution - 0017, Changsha

430022

Local Institution, Wuhan

450008

Local Institution, Zhengzhou

510080

Local Institution, Guangzhou

710038

Local Institution, Xi'an

830011

Local Institution, Ürümqi

Unknown

Local Institution, Guangzhou